CN108420891A - A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia - Google Patents
A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia Download PDFInfo
- Publication number
- CN108420891A CN108420891A CN201810265730.2A CN201810265730A CN108420891A CN 108420891 A CN108420891 A CN 108420891A CN 201810265730 A CN201810265730 A CN 201810265730A CN 108420891 A CN108420891 A CN 108420891A
- Authority
- CN
- China
- Prior art keywords
- food
- preparation
- parts
- health products
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 240000002547 Rosa roxburghii Species 0.000 claims abstract description 21
- 235000000640 Rosa roxburghii Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 201000005569 Gout Diseases 0.000 claims abstract description 17
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 15
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 15
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 11
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 230000036541 health Effects 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 241000220317 Rosa Species 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 22
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 21
- 229940116269 uric acid Drugs 0.000 description 21
- 238000002156 mixing Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 15
- 235000013616 tea Nutrition 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 11
- 241001122767 Theaceae Species 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 241000229143 Hippophae Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 229960002529 benzbromarone Drugs 0.000 description 4
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000002932 luster Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CPWPJLJWUXOOAB-UHFFFAOYSA-N benzene;bromine Chemical compound [Br].C1=CC=CC=C1 CPWPJLJWUXOOAB-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000035911 sexual health Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of compositions and its preparation method and application for preventing and/or treating hyperuricemia, it is the preparation that the raw material matched containing following weight is prepared：30~50 parts of Rosa roxburghii Tratt, 10~30 parts of Pu'er tea.The composition further includes following raw material：5~20 parts of 10~30 parts of pueraria lobata and/or sea-buckthorn.The results show, compared with the drug of existing treatment hyperuricemia and gout, composition of the invention is more safe and effective, and a kind of new selection is provided for clinical application.And the present composition is medicine-food two-purpose, safe and non-toxic, functional health-care food can be used as to be eaten for a long time, have a vast market application prospect.
Description
Technical field
The present invention relates to a kind of compositions and its preparation method and application for preventing and/or treating hyperuricemia.
Background technology
Uric acid is the final product of human body purine metabolism, is mainly generated by liver metabolism, and kidney excretion goes out in vitro.Antihyperuricemic
Disease (hyperuricemia, HUA) is that uric acid is excessive or kidney excretion uric acid is reduced since liver metabolism generates in blood, or
The reason of the two has concurrently generates uric acid in blood level and increases, and even higher than blood uric acid generates saturated concentration (416.5 μ of crystallization
Mol/L pathological state).Patients with Hyperuricemia can be precipitated because of monosodium urate salt (monosodium, MSU) crystal and gradually accumulate
It is tired to induce gout, it is also possible to symptom do not occur, but the uric acid total amount of patient's body will be apparently higher than normal person in the case of two kinds
Group.In recent years, with the improvement of people's living standards, the change of dietary structure and living habit, the illness rate of hyperuricemia
Increase year by year, epidemiological study data shows that the morbidity of hyperuricemia and primary gout is in rising trend, in China,
Through there is 1.2 hundred million HUA crowd, the 10% of total population is accounted about, person in middle and old age and postclimacteric women are group of people at high risk, are sent out in recent years
The sick age is also in the trend of rejuvenation.
Currently, the drug of clinical treatment hyperuricemia is generally divided into three classes.(1) releasing uric acid prescription medicine：Uricosuric
Include mainly probenecid, Sulfinpyrazone, Benzbromarone etc..Such drug can prevent reabsorption of the renal tubule to uric acid, increase urine
The discharge of acid, to play the role of reducing serum uric acid level in human body, also human body while side effect multiple rows of uric acid
Other trace elements also excrete, and can cause low blood sodium, Diagnostic value, low blood calcium, so use cannot be grown, but also to liver, kidney
There is side effect, use can not be grown.(2) drug for inhibiting uric acid to generate：The drug for clinically commonly uric acid being inhibited to generate is other
Fast alcohol, the medicine are a kind of purine oxidase inhibitor of strength, can effectively reduce uric acid and generate, reduce uric acid level in human body
Drug, but Allopurinol has the side effects such as the systemic allergics symptoms such as generation fash, poisoning syndrome, bone marrow suppression, hepatic injury,
It is very careful using upper requirement.(3) drug of alkalized urine：The alkalinity medicine such as sodium bicarbonate, potassium citrate and citron mixture acid
Object this acted on without anti-trioxypurine but can alkalized urine, increase solubility of the uric acid in blood, uric acid made to be not easy to gather and shape in urine
At crystallization.Calculus urate action speed is treated in phleboclysis, and common drug has sodium lactate solution and 5% sodium bicarbonate molten
Liquid, due to the use of when need close observation blood pressure situations such as, it is therefore desirable to hospitalization；Oral sodium bicarbonate is the most convenient, still
May easily cause and have a stomach upset, before beging half an hour be administered at empty stomach, because stomach is acidic environment, especially feed after be even more such as
This, and in stomach long-time indwelling stomach, at this moment such as eating sodium bicarbonate alkaline drug can neutralize with hydrochloric acid in gastric juice quickly, can not absorb
Enter blood and flow into kidney alkalized urine, and many gases generated keep stomach more glutted, the people if any stomach trouble such as gastric ulcer is easy
Bleeding and perforation.
Therefore, it is badly in need of a kind of safe, treatment hyperuricemia without side-effects composition now.
Invention content
In order to solve the above technical problem, the present invention provides a kind of foods for preventing and/or treating hyperuricemia
Product, health products or pharmaceutical composition, it is the preparation that the raw material matched containing following weight is prepared：30~50 parts of Rosa roxburghii Tratt,
10~30 parts of Pu'er tea.
Further, it is the preparation that the raw material matched containing following weight is prepared：40 parts of Rosa roxburghii Tratt, Pu'er tea 20
Part.
Further, the composition further includes following raw material：5~20 parts of 10~30 parts of pueraria lobata and/or sea-buckthorn.
Further, the pueraria lobata is 20 parts, and the sea-buckthorn is 10 parts.
Further, the Rosa roxburghii Tratt is rose family rose rosa roxburghii Rosa roxburghii Tratt and single-lobe
The fruit of rosa roxburghii.
Further, it is active constituent that it, which is by the medicinal powder of bulk pharmaceutical chemicals, the water of bulk pharmaceutical chemicals or extractive with organic solvent, in addition
The preparation that acceptable auxiliary material or complementary ingredient are prepared in pharmacy.
Further, the preparation is oral preparation；Preferably, the oral preparation is decoction, powder, capsule, piece
Agent, granule.
The present invention also provides a kind of methods preparing above-mentioned food, health products or pharmaceutical composition, it includes following step
Suddenly：
1) each raw material is weighed by weight ratio；
2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, and in pharmacy acceptable auxiliary material or it is complementary at
Divide and is prepared into preparation.
The present invention also provides above-mentioned composition prepare prevent and/or the treatment food of hyperuricemia, health products or
Purposes in drug.
The present invention also provides above-mentioned compositions in the food, health products or drug for preparing prevention and/or treatment gout
Purposes.
The results show, compared with the drug of existing treatment hyperuricemia and gout, composition of the invention is more
Safely and effectively, a kind of new selection is provided for clinical application.And the present composition is medicine-food two-purpose, safe and non-toxic, can
To be eaten for a long time as functional health-care food, application prospect is had a vast market.
Obviously, the above according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific implementation mode of form by the following examples remakes further specifically the above of the present invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on the above of the present invention
The technology realized all belongs to the scope of the present invention.
Specific implementation mode
The preparation of embodiment 1, food of the present invention, health products or pharmaceutical composition
It since tea bag is across tea beverage, health products, three big gold industry of medicinal herb tea, can not only sip tea, but also energy health care, and can support
It is raw.It is specific as follows the following provide the preparation method of teabag of food of the present invention, health products or pharmaceutical composition：
1 prescription：Rosa roxburghii Tratt 4.0g, Pu'er tea 2.0g
2 occupation modes：It is directly brewed and is drunk with boiling water.
The preparation of embodiment 2, food of the present invention, health products or pharmaceutical composition
1 prescription：Rosa roxburghii Tratt 40g, Pu'er tea 20g, pueraria lobata 20g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 3, food of the present invention, health products or pharmaceutical composition
1 prescription：Rosa roxburghii Tratt 40g, Pu'er tea 20g, sea-buckthorn 10g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 4, food of the present invention, health products or pharmaceutical composition
1 prescription：Rosa roxburghii Tratt 40g, Pu'er tea 20g, pueraria lobata 20g, sea-buckthorn 10g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 5, food of the present invention, health products or pharmaceutical composition
1 prescription：Rosa roxburghii Tratt 50g, Pu'er tea 30g, pueraria lobata 30g, sea-buckthorn 20g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 6, food of the present invention, health products or pharmaceutical composition
1 prescription：Rosa roxburghii Tratt 30g, Pu'er tea 20g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 7, food of the present invention, health products or pharmaceutical composition
1 prescription：Rosa roxburghii Tratt 30g, Pu'er tea 10g, pueraria lobata 10g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 8, food of the present invention, health products or pharmaceutical composition
1 prescription：Rosa roxburghii Tratt 30g, Pu'er tea 10g, sea-buckthorn 5g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
Illustrate beneficial effects of the present invention below by way of the mode of test example.
The sensory evaluation of test example 1, the present composition
Randomly select subject 167,23-70 years old ages, male 97, women 70.Embodiment 1,2,3,4 is drunk in examination
The composition of preparation is judged in terms of mouthfeel, color and luster, fragrance 3 respectively.
Judgment criteria：
Mouthfeel amounts to 10 points：1~5 point to represent mouthfeel poor；6~7 points indicate that mouthfeel is general, are subjected to；8~10 points of expressions
It is in good taste.
Color and luster amounts to 10 points：1~5 point indicates that color and luster is muddy；6~7 points indicate that color is general；8~10 points indicate that color and luster is equal
It is even transparent.
Fragrance amounts to 10 points：1~5 point indicates that smell is unpleasant；6~7 points indicate that smell is general, are subjected to；8~10 points
Indicate that fragrant odour is pleasant.
Experimental result is shown in Table 1.
The sense organ evaluating meter of 1 present composition of table
As can be seen from the above table, for the present composition as food, mouthfeel is excellent；As drug, patient can be mitigated not
Good medication impression.
Test example 2, hyperuricemia clinical case statistics
(1) patient criteria is accepted for medical treatment
Patients with Hyperuricemia, 30-70 years old ages, male 50, women 30.
(2) diagnostic criteria of hyperuricemia
Under normal purine diet state, non-empty stomach serum uric acid level male twice on the same day>416 μm of ol/L (7mg/dl),
Women>357 μm of ol/L (6mg/dl), as hyperuricemia.
(3) standard is treated
It is effective：The empty stomach blood uric acid value of experiment Patients Before And After drops to normal blood uric acid value.
Effectively：Testing the empty stomach serum uric acid level of Patients Before And After reduces by 20% or more.
In vain：The empty stomach serum uric acid level of Patients Before And After is tested without reduction.
(4) therapy
1) medication：After clarifying a diagnosis, treatment group is treated using composition prepared by the embodiment of the present invention 4；It is right
It is treated using benzbromarone tablets according to group.
Treatment group：40 patients are all made of following drug：Rosa roxburghii Tratt 40g, Pu'er tea 20g, pueraria lobata 20g, sea-buckthorn 10g.It prepares
Process：Above-mentioned each raw material is weighed, mixing is beaten powder, is sieved with 100 mesh sieve, and all after mixing, is dispensed by every bag of 3g, irradiation sterilization,
Tea bag is made.Application method：Boiling water is taken after mixing it with water, and three times a day, 1 bag every time, 12 weeks as a treatment course.
Control group：Benzbromarone tablets, 50mg*10 pieces, Kunshan dragon lantern Rui Di pharmaceutical Co. Ltds, lot number 161005 use
Method：Oral 50mg (1) every time, once a day, early to take after the meal, 3 weeks as a treatment course
2) without apparent medication taboo, without other complications.
(5) treatment results
Treatment time：12 weeks
Efficacy determination：The results are shown in Table 2
2 hyperuricemia Comparison of therapeutic table of table
From the above it is found that the composition of the present invention is suitable with the therapeutic effect of benzbromarone tablets, but take benzene bromine
After grand of horse, often there is digestive discomfort sense (such as nausea, vomitting, feeling of repletion and diarrhea etc. in stomach), scratchiness, face hair in patient
The adverse reactions such as red, erythema, photoallergy, edema, precordial region sense of discomfort.And after taking the composition of the present invention, patient will not
There is any adverse reaction.Therefore, compared with existing drug, composition of the invention is safer.
Test example 3, gout clinical case statistics
(1) patient criteria is accepted for medical treatment
Patient with gout, 23-70 years old ages, male 47, women 40
(2) diagnostic criteria of gout
The gout contingency table released with reference to American society of rheumatism in 2015 and European rheumatism alliance ACR/Eular joints
Standard, criteria for classification include 3 projects, and 8 entries amount to 23 points, but need to only meet 8 points can be diagnosed as gout, and details are shown in Table
3：
3 gout diagnostic criteria of table
(3) standard is treated
It is effective：Gout score value reduces by 40%.
Effectively：Gout score value reduces by 20%.
In vain：Gout score value is without reduction.
(4) therapy
1) medication：After clarifying a diagnosis, treatment group is treated using composition prepared by the embodiment of the present invention 4；It is right
Effects of Colchicine In Treating is used according to group.
Treatment group：44 patients are all made of following drug：Rosa roxburghii Tratt 40g, Pu'er tea 20g, pueraria lobata 20g, sea-buckthorn 10g.It prepares
Process：Above-mentioned each raw material is weighed, mixing is beaten powder, is sieved with 100 mesh sieve, and all after mixing, is dispensed by every bag of 5g, irradiation sterilization,
Tea bag is made.Application method：Boiling water is taken after mixing it with water, and three times a day, 1 bag every time, 5 weeks as a treatment course.
Control group：Colchicines tablets, 0.5mg*20 pieces, Yunnan Plant Pharmaceutical Industry Co., Ltd., lot number 20170202.User
Method：Acute stage：Adult's usual amounts are to take 0.5~1mg (1~2) in every 1~2 hour, until joint symptoms are alleviated, or abdomen occur
It rushes down or vomits, reach therapeutic dose and be generally 3~5mg (6~10), no more than 6mg (12) in 24 hours, withdraw 72 hours
Afterwards daily dose be 0.5-1.5mg (1~3), part vic, totally 7 days.Prevent：0.5~1mg (1~2) on the one takes by several times
With.
2) without apparent medication taboo, without other complications.
(5) treatment results
Treatment time：12 weeks
Efficacy determination：The results are shown in Table 4
4 gout Comparison of therapeutic table of table
From the above it is found that the composition of the present invention is better than the therapeutic effect of colchicines tablets, provided for clinical application
A kind of new selection；And the composition of the present invention has no toxic side effect, and safety can for a long time be eaten as functional health-care food
With.
To sum up, compared with the drug of existing treatment hyperuricemia and gout, composition of the invention is more safe and effective,
A kind of new selection is provided for clinical application.And the present composition is medicine-food two-purpose, safe and non-toxic, can be used as function
Sexual health food is eaten for a long time, and has a vast market application prospect.
Claims (10)
1. a kind of food, health products or pharmaceutical composition for preventing and/or treating hyperuricemia, it is characterised in that：It
It is the preparation that the raw material matched containing following weight is prepared：30~50 parts of Rosa roxburghii Tratt, 10~30 parts of Pu'er tea.
2. food according to claim 1, health products or pharmaceutical composition, it is characterised in that：It is containing following weight
The preparation that the raw material of proportioning is prepared：40 parts of Rosa roxburghii Tratt, 20 parts of Pu'er tea.
3. food according to claim 1 or 2, health products or pharmaceutical composition, it is characterised in that：The composition also wraps
Include following raw material：5~20 parts of 10~30 parts of pueraria lobata and/or sea-buckthorn.
4. food according to claim 3, health products or pharmaceutical composition, it is characterised in that：The pueraria lobata is 20 parts, institute
It is 10 parts to state sea-buckthorn.
5. food according to claims 1 to 4, health products or pharmaceutical composition, it is characterised in that：The Rosa roxburghii Tratt is rose
The fruit of section rose rosa roxburghii Rosa roxburghii Tratt and single-lobe rosa roxburghii.
6. according to Claims 1 to 5 any one of them food, health products or pharmaceutical composition, it is characterised in that：It is by original
Expect that the medicinal powder of medicine, the water of bulk pharmaceutical chemicals or extractive with organic solvent are active constituent, in addition acceptable auxiliary material or auxiliary in pharmacy
The preparation that helping property ingredient is prepared.
7. according to claim 1~6 any one of them food, health products or pharmaceutical composition, it is characterised in that：The preparation
For oral preparation；Preferably, the oral preparation is decoction, powder, capsule, tablet, granule.
8. a kind of method preparing any one of claim 1~7 food, health products or pharmaceutical composition, it is characterised in that：
It includes the following steps：
1) each raw material is weighed by weight ratio；
2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, in addition acceptable auxiliary material or complementary ingredient system in pharmacy
For at preparation.
9. any one of claim 1~7 composition is preparing food, the health products for preventing and/or treating hyperuricemia
Or the purposes in drug.
10. any one of claim 1~7 composition is preparing food, health products or the drug for preventing and/or treating gout
In purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810265730.2A CN108420891A (en) | 2018-03-28 | 2018-03-28 | A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810265730.2A CN108420891A (en) | 2018-03-28 | 2018-03-28 | A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108420891A true CN108420891A (en) | 2018-08-21 |
Family
ID=63159477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810265730.2A Pending CN108420891A (en) | 2018-03-28 | 2018-03-28 | A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108420891A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526263A (en) * | 2011-12-20 | 2012-07-04 | 瑞坝（北京）新能源科技有限公司 | Plant health care product for preventing and treating gout |
| CN105902687A (en) * | 2016-05-24 | 2016-08-31 | 姚德林 | Health-care tea for treating gout and preparation method thereof |
| CN106421427A (en) * | 2016-11-17 | 2017-02-22 | 兴义市东泰天然果蔬开发有限公司 | Tea for gout |
-
2018
- 2018-03-28 CN CN201810265730.2A patent/CN108420891A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526263A (en) * | 2011-12-20 | 2012-07-04 | 瑞坝（北京）新能源科技有限公司 | Plant health care product for preventing and treating gout |
| CN105902687A (en) * | 2016-05-24 | 2016-08-31 | 姚德林 | Health-care tea for treating gout and preparation method thereof |
| CN106421427A (en) * | 2016-11-17 | 2017-02-22 | 兴义市东泰天然果蔬开发有限公司 | Tea for gout |
Non-Patent Citations (5)
| Title |
|---|
| 中国特产大典编审委员会贵州卷编委会: "《中国特产大典贵州卷》", 31 March 2011, 贵州人民出版社 * |
| 史珅: "葛根提取物对高尿酸血症大鼠血尿酸的影响", 《食品科技》 * |
| 王友兰等: "普洱茶提取物对高尿酸血症模型小鼠血尿酸的影响 ", 《内蒙古中医药》 * |
| 贵州省科学技术情报研究所，贵州省科技发展战略研究院: "《贵州省中药材大品种产业链 第1部》", 30 September 2017, 贵州科技出版社 * |
| 郭小李: "越桔黄酮对高尿酸血症的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
| EP1588711A1 (en) | Composition trapping radicals in organism | |
| CN108882744A (en) | Contain intelligence development extract as effective component for preventing, improving or treating the composition of hyperuricemia or dysbolism relevant to hyperuricemia | |
| DE3319575A1 (en) | THERAPEUTICALLY EFFECTIVE COMPOSITIONS, FOOD AND BEVERAGES | |
| JP2005330273A (en) | Free radical-scavenging composition in living body | |
| KR101721145B1 (en) | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement | |
| KR20040106367A (en) | Difructose anhydride-containing composition and use thereof | |
| CN108310123A (en) | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia | |
| JP2006273797A (en) | Composition for suppressing rise of blood sugar value and the like, food for suppressing rise of blood sugar value and the like, and disaccaride hydrolase activity inhibiting composition | |
| CN108420891A (en) | A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia | |
| JP3634721B2 (en) | Preventive or therapeutic agent for hyperlipidemia | |
| CN1315411C (en) | Health-care food with functions of relaxing the bowels and beautifying, and its prepn. method | |
| US20210023097A1 (en) | Methylphosphinic acid compositions and methods for reducing aging | |
| KR100584153B1 (en) | Manufacture method, Various uses and Extracts for The Development of Anticonspitation Functional food materials from Oriental Herbal Medicines | |
| WO2008096171A2 (en) | Natural laxative composition comprising prunes, raisins, apricots, dates, figs, olive oil, senna and honey | |
| CN104800686B (en) | A kind of pharmaceutical composition for treating sequelae of eating and drinking immoderately and its preparation method and application | |
| CN113712982B (en) | Composition for preventing or treating non-alcoholic fatty liver disease and obesity, and preparation method and application thereof | |
| TWI784169B (en) | Prevention or improvement agent for nocturnal frequent urination | |
| CN110339229B (en) | Viscosity-reducing and blood-clearing composition and application thereof | |
| CN109223803A (en) | Improve the composition and preparation process of energy and blood of human body function delaying human body caducity | |
| CN104490988B (en) | A kind of composition and preparation method thereof and purposes improving menopausal syndrome symptom | |
| CN113663047A (en) | Composition with kidney tonifying and bone strengthening effects and preparation method thereof | |
| CN104069256A (en) | Drug composition used for preventing birth defects and improving memory | |
| CN104069259A (en) | Medicinal composition for preventing birth defects and improving memory | |
| CN104069257A (en) | Drug composition used for preventing birth defects and improving memory |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180821 |